Sacituzumab govitecan

MCE 國際站：Sacituzumab govitecan

CAS：1491917-83-9

品牌：MedChemExpress (MCE)

存儲條件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Sacituzumab govitecan (IMMU-132) 是一種抗體-藥物偶聯(lián)物 (ADC)，靶向 Trop-2 以遞送 SN-38,。 Sacituzumab govitecan 具有抗癌活性^[1],。 體內： Sacituzumab govitecan (IMMU-132)（17.5 mg/kg；每周兩次,，持續(xù) 4 周）對攜帶人胃癌異種移植物的小鼠產(chǎn)生顯著的抗腫瘤作用^[1],。

研究領域：Antibody-drug Conjugate/ADC Related

作用靶點：Antibody-Drug Conjugates (ADCs)

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻：

[1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. [2]. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6(26):22496-22512.